Back to Search Start Over

Reply

Authors :
Peter A. Merkel
Carol A. Langford
Philip Seo
Sharon A. Chung
Source :
Arthritis & Rheumatology. 74:545-546
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

We appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.

Subjects

Subjects :
medicine.medical_specialty
Cyclophosphamide
business.industry
Immunology
Guideline
medicine.disease
Dermatology
Rheumatology
Remission induction
immune system diseases
Internal medicine
medicine
Immunology and Allergy
Rituximab
Granulomatosis with polyangiitis
business
Microscopic polyangiitis
Vasculitis
medicine.drug

Details

ISSN :
23265205 and 23265191
Volume :
74
Database :
OpenAIRE
Journal :
Arthritis & Rheumatology
Accession number :
edsair.doi.dedup.....70a611f29b3a13e5839f7ef2d143c5b7
Full Text :
https://doi.org/10.1002/art.41991
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details